Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
AbstractPsoriasis is a systemic immune-mediated disease associated with an increased risk of comorbidities, such as psoriatic arthritis, cardiovascular disease, metabolic syndrome, inflammatory bowel disease, psychiatric disorders, and malignancy. In recent years, with the advent of biological agents, the efficacy and safety of psoriasis treatments have dramatically improved. Presently, tumor necrosis factor- α inhibitors, interleukin-17 inhibitors, interleukin-12/23 inhibitors, and interleukin-23 inhibitors are approved to treat moderate-to-severe psoriasis. Small-molecule inhibitors, such as apremilast and deucravacitin...
Source: BioDrugs - January 2, 2023 Category: Drugs & Pharmacology Source Type: research
Malaysian Hospital Pharmacists ’ Perspectives and Their Role in Promoting Biosimilar Prescribing: A Nationwide Survey
ConclusionAlthough Malaysian pharmacists are in favour of biosimilars, they lack training to promote biosimilar use. Among the factors associated with successful promotion of biosimilars to prescribers are pharmacist confidence, their previous experience handling biosimilars, and prior biosimilar training. (Source: BioDrugs)
Source: BioDrugs - December 26, 2022 Category: Drugs & Pharmacology Source Type: research
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy
AbstractThe clinical approval of immune checkpoint inhibitors is an important advancement in the field of cancer immunotherapy. However, the percentage of beneficiaries is still limited and it is becoming clear that combination therapies are required to further enhance the treatment efficacy. The potential of strategies targeting the immunoregulatory network by “hitting the gas pedal” as opposed to “blocking the brakes” is being recognized and intensively investigated. Hence, next to immune checkpoint inhibitors, agonists of co-stimulatory receptors of the tumor necrosis factor superfamily (TNF-SF) are emerging as ...
Source: BioDrugs - December 26, 2022 Category: Drugs & Pharmacology Source Type: research
Malaysian Hospital Pharmacists ’ Perspectives and Their Role in Promoting Biosimilar Prescribing: A Nationwide Survey
ConclusionAlthough Malaysian pharmacists are in favour of biosimilars, they lack training to promote biosimilar use. Among the factors associated with successful promotion of biosimilars to prescribers are pharmacist confidence, their previous experience handling biosimilars, and prior biosimilar training. (Source: BioDrugs)
Source: BioDrugs - December 26, 2022 Category: Drugs & Pharmacology Source Type: research
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy
AbstractThe clinical approval of immune checkpoint inhibitors is an important advancement in the field of cancer immunotherapy. However, the percentage of beneficiaries is still limited and it is becoming clear that combination therapies are required to further enhance the treatment efficacy. The potential of strategies targeting the immunoregulatory network by “hitting the gas pedal” as opposed to “blocking the brakes” is being recognized and intensively investigated. Hence, next to immune checkpoint inhibitors, agonists of co-stimulatory receptors of the tumor necrosis factor superfamily (TNF-SF) are emerging as ...
Source: BioDrugs - December 26, 2022 Category: Drugs & Pharmacology Source Type: research
Acknowledgement to Referees
(Source: BioDrugs)
Source: BioDrugs - December 19, 2022 Category: Drugs & Pharmacology Source Type: research
Current Developments in the Preclinical and Clinical use of Natural Killer T cells
AbstractNatural killer T (NKT) cells play a pivotal role as a bridge between the innate and the adaptive immune response and are instrumental in the regulation of homeostasis. In this review, we discuss the potential for NKT cells to serve as biodrugs in viral infections and in cancer. NKT cells are being investigated for their use as a prognostic biomarker, an immune adjuvant, and as a form of cellular therapy. Historically, the clinical utility of NKT cells was hampered by their low frequency in the blood, discrepancies in nomenclature, and challenges with ex vivo expansion. However, recent advances in the field have per...
Source: BioDrugs - December 16, 2022 Category: Drugs & Pharmacology Source Type: research
Complement Inhibition in Kidney Transplantation: Where Are We Now?
AbstractKidney transplantation is a life-saving strategy for patients with end-stage renal disease. Although progress has been made in the field of transplantation medicine in recent decades in terms of surgical techniques and immunosuppression, long-term organ survival remains a challenge. Also, for reasons of organ shortage, there is an unmet need for new therapeutic approaches to improve the long-term survival of transplants. There is increasing evidence that the complement system plays a crucial role in various pathological events after transplantation, including ischemia/reperfusion injury as well as rejection episode...
Source: BioDrugs - December 13, 2022 Category: Drugs & Pharmacology Source Type: research
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
ConclusionsWith this study, we try to contribute to discussions on creating more transparency about global approvals of follow-on biologics and promoting access to high-quality biosimilars in countries around the world. (Source: BioDrugs)
Source: BioDrugs - December 6, 2022 Category: Drugs & Pharmacology Source Type: research
